Literature DB >> 25819590

Mirabegron.

Sebastiaan C Goulooze1, Adam F Cohen1,2, Robert Rissmann1,2.   

Abstract

Mirabegron is used for the treatment of symptoms associated with overactive bladder syndrome. It selectively stimulates the β3 -adrenoreceptor, which relaxes the detrusor muscle. This improves urine storage by distension of the bladder body.
© 2015 The British Pharmacological Society.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25819590      PMCID： PMC4594713          DOI： 10.1111/bcp.12647

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  8 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  Neurophysiology of lower urinary tract function and dysfunction.

Authors:  Naoki Yoshimura; Michael B Chancellor
Journal:  Rev Urol       Date:  2003

Review 3.  Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.

Authors:  Christopher R Chapple; Linda Cardozo; Victor W Nitti; Emad Siddiqui; Martin C Michel
Journal:  Neurourol Urodyn       Date:  2013-10-11       Impact factor: 2.696

Review 4.  Defining overactive bladder: epidemiology and burden of disease.

Authors:  Andrea Tubaro
Journal:  Urology       Date:  2004-12       Impact factor: 2.649

5.  Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.

Authors:  Christopher Chapple; Vik Khullar; Victor W Nitti; Jeffrey Frankel; Sender Herschorn; Mathilde Kaper; Mary Beth Blauwet; Emad Siddiqui
Journal:  Eur Urol       Date:  2014-08-02       Impact factor: 20.096

Review 6.  Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors.

Authors:  Elfaridah P Frazier; Stephan L M Peters; Alan S Braverman; Michael R Ruggieri; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-04       Impact factor: 3.000

7.  Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.

Authors:  Yasuhiko Igawa; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-21       Impact factor: 3.000

8.  The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.

Authors:  D Castro-Diaz; C R Chapple; Z Hakimi; M B Blauwet; L Delgado-Herrera; W Lau; S Mujais
Journal:  Qual Life Res       Date:  2015-02-17       Impact factor: 4.147
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.